Multiple primary malignant tumors in patients with Hodgkin’s lymphoma

DOI: https://doi.org/10.29296/25877305-2019-11-01
Download full text PDF
Issue: 
11
Year: 
2019

S. Shakhtatina(1), MD; A. Danilenko(1), MD; N. Falaleeva(1), MD; S. Ivanov(1), MD; Professor A. Kaprin(2), MD, Academician of the Russian Academy of Sciences 1-A.F. Tsyb Medical Radiology Research Center, Branch National Medical Radiology Research Center, Ministry of Health of Russia, Obninsk 2-National Medical Radiology Research Center, Moscow

The presence of ≥2 malignant neoplasms of different genesis in a patient is considered as a multiple primary malignant tumor. Hodgkin’s lymphoma (HL) is recognized as a potentially treatable disease. The increase in the life expectancy of patients necessitates an examination of 2 (metachronous) malignant tumors in these patients. The incidence of metachronous malignant tumors in patients with HL is higher than that in the population, which should be taken into account during a follow-up.

Keywords: 
oncology
Hodgkin’s lymphoma
metachronous malignant tumor
relative risk



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Zlokachestvennye novoobrazovanija v Rossii v 2017 g. (zabolevaemost' i smertnost'). Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoj / M.: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2018; 250 s. [Malignant neoplasms in Russia in 2017 (morbidity and mortality). Edited by A.D. Kaprina, V.V. Starinsky, G.V. Petrova / M.: Moscow them. P.A. Herzen – a branch of the Federal Research Center of Radiology Research Center of the Ministry of Health of Russia, 2018; 250 p. (in Russ.)].
  2. Davydov M.I., Aksel' E.M. Statistika zlokachestvennyh zabolevanij v Rossii i stranah SNG v 2008 g. // Vestnik RONTs im. Blohina RAMN. – 2010; 21 (2, pril. 1): 52–9 [Davydov M.I., Axel E.M. Statistics of malignant diseases in Russia and the CIS countries in 2008 // Vestnik RONTs im. Blokhina RAMN. – 2010; 21 (2, suppl. 1): 52–9 (in Russ.)].
  3. Vanderbroucke J. A shortcut method for calculating the 95 per cent confidence interval of the standardized mortality ratio // Am. J. Epidemiol. – 1982; 115: 303–4.
  4. Danilenko A.A., Shahtarina S.V. Limfoma Hodzhkina i vtorye zlokachestvennye opuholi // Vopr. onkol. – 2009; 55 (6): 692–702 [Danilenko A.A., Shakhtarina S.V. Hodgkin’s lymphoma and second malignant tumors // Vopr. onkol. – 2009; 55 (6): 692–702 (in Russ.)].
  5. Shakhtarina, S., Danilenko A., Pavlov V. Second cancer risks in patients with supradiaphragmatic Hodgkin lymphoma // Haematologica. – 2016; 101 (Suppl. 5): 71.
  6. Kumar V., Mohit G., Chandra Ad. et al. Trends in the risks of secondary cancers in patients with Hodgkin Lymphoma // Clinical Lymphoma, Myeloma & Leukemia. – 2018; 18 (9): 576–89.
  7. Von Tresckow B., Kreissl S., Goergen H. et al. Intensive treatment strategies in advanced-stage Hodgkin`s lumphoma (HD 9 and HD 12): analisis of long-term survival in two randomized trials // Lancet Haematol. – 2018; 10: e462–e473. DOI: 10.1016/S2352-3026(18)30140-6.
  8. Wolden S., Hancock S., Carlson R. et al. Management of breast cancer after Hodgkin’s disease // J. Clin. Oncol. – 2000; 18: 765–72.
  9. Ibrahim E., Abouelkhair K., Kazkaz G. et al .Risk of second breast cancer in female Hodgkin`s Lymphoma survivors: a meta-analysis // BMC Cancer. – 2012; 12: 197. http://doi.org/10.1186/1471-2407-12-197.
  10. Koh E., Trun T., Heydarian M. A comparison of mantle versus involved-field radiotherapy for Hodgkin`s Lymphoma: reduction an normal tissue dose and second cancer risk // Radiation Oncology. – 2007; 2: 13. http://doi.org/10.1186/1748-717X-2-13.
  11. Journi N., Mansouri I., Allodji R. et. al. Volume effects of radiotherapy on the risk of secondary primary cancers: A systematic review of clinical and epidemiological studies // Radiother. Oncol. – 2018; pii: S0167–8140(18)33500-X. DOI: 10.1016/j.radonc.2018.09.017.
  12. Travis L., Gospodarowicz M., Curtis R. et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease // J. Nat. Cancer Inst. – 2002; 94 (3): 182–92.
  13. Shahtarina S.V., Danilenko A.A., Pavlov V.V. i dr. Vlijanie protivoopuholevoj lekarstvennoj i luchevoj terapii na sostojanie schitovidnoj zhelezy u bol'nyh limfomoj Hodzhkina v otdalennye sroki nabljudenija // Klin. onkogematol. – 2014; 7 (4): 533–9 [Shakhtarina S.V., Danilenko A.A., Pavlov V.V. et al. Influence of antitumor drug and radiation therapy on the state of the thyroid gland in patients with Hodgkin’s lymphoma in the long-term follow-up period // Clin. Oncohematol. – 2014; 7 (4): 533–9 (in Russ.)].
  14. Kaprin A.D., Galkin V.N., Zhavoronkov L.P. i dr. Sintez fundamental'nyh i prikladnyh issledovanij – osnova obespechenija vysokogo urovnja nauchnyh rezul'tatov i vnedrenija ih v meditsinskuju praktiku // Radiatsija i risk. – 2017; 26 (2): 26–40 [Kaprin A.D., Galkin V.N., Zhavoronkov L.P. et al. Synthesis ofbasic and applied research is the basis ofobtaining high-quality findingsand translatingthem intoclinicalpractice // Radiation and risk. – 2017; 26 (2): 26–40 (in Russ.)].